Hints and tips:
Related Special Reports
...Read the full story, from the FT’s Bryan Harris and Michael Stott in Brazil, here....
...Rivals AstraZeneca, Johnson & Johnson, Russia’s Sputnik V and new entrants such as Novavax make up the remainder of the market, which is forecast to double in value to $124bn next year....
...A version of this article was first published by Nikkei Asia on July 27. ©2022 Nikkei Inc. All rights reserved....
...Despite the delays, however, Mr Pazuello has predicted Brazil will “very soon” be exporting vaccines given the country’s pharmaceutical manufacturing capabilities....
...“Africa is a key market for Sputnik V,” said the Russian Direct Investment Fund, a Kremlin-run wealth fund overseeing Sputnik V’s foreign sales....
...The day before, Sputnik V, a Russian vaccine made by the Gamaleya Institute, showed 92 per cent efficacy against symptomatic Covid, according to preliminary data published in the Lancet....
...Surveys conducted by The Harris Poll found that approval of the pharmaceutical industry had almost doubled from 32 per cent in January last year to 62 per cent in February this year....
...After such strong reads from the first two releases (three if we count Russia’s Sputnik V), the disappointing AZN figures were perhaps bound to prompt downward pressure on the company’s shares....
...Additional reporting by Bryan Harris in Sao Paulo and Guy Chazan in Berlin...
...In August, Russia became the first country to approve a Covid-19 vaccine — named Sputnik V — for civilian use, but western experts cast doubt on its efficacy and safety....
...If there is a sense from this earnings season that confidence in a V-shaped recovery for profits is misplaced, then the impact will probably be hardest on companies with weak balance sheets, and on those...
...Beyond these three biotechs, Crispr could end up transforming the entire pharmaceutical industry....
...Their concentrated ownership of industries such as airlines and pharmaceuticals may push up travel and drug prices, some academics argue....
...In 2015, he advised Mylan on a successful defence against a hostile bid by Teva Pharmaceuticals....
...sweeping bills to shake up the pharmaceutical market....
...She worked as a janitorial supervisor at C&W client Lonza, a Swiss pharmaceuticals group, which has a production facility in Portsmouth, New Hampshire....
...While the Recordati family sold a majority of their shares in their pharmaceuticals company to the US private equity group CVC in July....
...Novartis has admitted paying $1.2m to an entity owned by Donald Trump’s personal lawyer in the year following his 2017 inauguration, drawing the Swiss pharmaceutical company deeper into a controversy over...
...Additional reporting by Bryan Harris in Seoul...
...He places human embryonic and pluripotent stem cells — that have the potential to grow into nearly every cell of the body — in tiny ‘U’ or ‘V’ shaped dishes in the lab to grow them into different types of...
...Pharmaceutical groups, which might see similar benefits from quantum technology in the long term, are still on the sidelines....
...Thanks to a series of court rulings since the mid-2000s, such as eBay v MercExchange in 2007, Mayo Collaborative Services v Prometheus Laboratories in 2012 and Alice Corp v CLS Bank in 2014, and the subsequent...
...the neuroscience business should not “shock investors but is likely to raise a debate over possible use of proceeds should any cash be generated and management of any earnings dilution [ie deleveraging v...
...A sprawling conglomerate composed of 62 affiliates covering everything from electronics to pharmaceuticals and heavy industry; Samsung is a bulwark of the South Korean economy....
...(The Atlantic) Man v machine Sensitivity to “gut feelings” is a strong predictor of success in financial trading, according to research led by Cambridge university....
International Edition